Project Grant R44HL186984
Award Date 9/1/26
Completion Date 7/31/28
Dollars Obligated $848K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Columbia, MD 21044, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded $598,636 to Spheric Bio Inc. on September 25, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop the EMULAATE platform, a patient-specific left atrial appendage occlusion (LAAO) device for stroke prevention in atrial fibrillation patients. Spheric Bio is developing EMULAATE to assemble fully soft, personalized implants directly inside the patient's body through a minimally invasive approach by delivering,...
- The National Heart, Lung, and Blood Institute awarded Corfigo, Inc. $447,736 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop the HeartPad Cryoablation System, a device for treating atrial fibrillation by performing full-thickness ablation of cardiac tissue from the epicardial surface on a beating heart. The HeartPad leverages liquid helium cooling and high-efficiency heat exchangers to ablate contiguous epicardial adipose tissue and atrial muscle...
- The National Heart, Lung, and Blood Institute awarded Pulsentry, Inc. $309,198 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and prototype an automated detection system for cardiac tamponade using existing fingertip pulse oximeters. Pulsentry will develop machine learning algorithms that analyze pulse waveform perturbations to identify early signs of cardiac tamponade, a medical emergency caused by fluid or clot accumulation around the heart...
- The National Heart, Lung, and Blood Institute awarded Aust Development, LLC a Phase I Small Business Innovation Research project grant of $626,604 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). Aust Development will develop a novel 3D pre-shaped delivery catheter platform to enable precise identification and safe delivery of cardiac conduction system pacing leads. The delivery system will allow physicians to sequentially map the septal myocardium, fix...
- The National Heart, Lung, and Blood Institute awarded $351,388 to Barron Associates, Inc. on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a noninvasive hemodynamic monitoring tool for heart failure patients. The project addresses the clinical gap in home and hospital monitoring of acute decompensated heart failure by creating a low-cost alternative to invasive right heart catheterization and costly implantable devices. The proposed solution...
- The National Heart, Lung, and Blood Institute awarded Coridea, LLC $305,365 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cooled radiofrequency bronchoscopic lung volume reduction technology for severe emphysema patients. The project addresses a clinical gap in lung volume reduction therapy. Current surgical options reach only a fraction of severe emphysema patients: wedge excision LVR surgery is invasive and limits candidate eligibility, while...
- The National Heart, Lung, and Blood Institute awarded $293,759 to Coridea, LLC on August 15, 2026, under the Cardiovascular Diseases Research SBIR program (CFDA 93.837) to develop a closed-loop percutaneous stellate ganglion nerve stimulation (SGNS) system for hemodynamic support in septic shock. Coridea will engineer a custom percutaneous neurostimulation lead with imaging-visible electrodes and fixation features to enable stable, reproducible access to the left stellate ganglion during patient...
- The National Heart Lung and Blood Institute awarded Inomagen Therapeutics, Inc. $1,412,149 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to advance IGN001, a non-viral short hairpin RNA plasmid designed to silence NOX2 and modify the disease substrate in atrial fibrillation without destroying atrial tissue. The recipient will conduct three aims: define the dose-dependent molecular activity and safety of IGN001 in healthy canines by assessing NOX2...
- The National Heart, Lung, and Blood Institute awarded Starlight Cardiovascular, Inc. $499,952 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 10, 2026, to advance commercialization of a catheter-delivered, adjustable percutaneous pulmonary flow restrictor designed to replace surgical pulmonary artery banding in newborns with hypoplastic left heart syndrome and other congenital heart defects. The flow restrictor addresses clinical limitations of current surgical...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Nimble Surgical Incorporated $314,362 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop FLEXLOCK, a manually operable anchoring guide catheter designed to simplify transradial complex percutaneous coronary interventions. FLEXLOCK delivers simultaneous active and passive support through an anchoring tip to provide stable coronary access during complex PCI...